Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MACoVIA: MultiStem Therapy in COVID-19 ARDS
NCT04367077Phase 3Terminated
- Sponsor
- Healios
- Start
- Apr 2020
- Primary completion
- Oct 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing MultiStem with Placebo (2 arms). Primary endpoints: Ventilator-Free Days at 28 days and Incidence of treatment-emergent adverse events at 28 days. Started Apr 2020; status: terminated.
02
Drugs
invimestrocel
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04367077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04367077.